Table 3.

Summary of combination of targeted-therapy trials in IDH1/2-mutant newly diagnosed AML

Regimens	Phase	Patient Number	CR/CRi rate, %	Time to CR or response (median), months	OS (median), months	References
HMA + venetoclax	Ib	35	71	2.1	24.4	[5]
AZA + venetoclax	III	46	75.4	N/A	N/A	[7]
AZA + venetoclax	Pooled data from two trials	79	72	1.0	24.5	[45]
LDAC + venetoclax (HMA naïve)	Ib/II III	18	72	1.4	19.4	[6, 8]
AZA + ivosidenib	Ib	23	69.6	3.7	N/A	[49]
AZA + enasidenib	II	68	68	5	22.0	[50]
Venetoclax + ivosidenib	Ib/II	12	83	NA	NA	[47]
AZA + venetoclax + ivosidenib	Ib/II	6	67	NA	NA	[47]